ArticleProtein science : a publication of the Protein Society2026
Limitations of the refolding pipeline for de novo protein design.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Zero-shot design of abioRxiv : the preprint server for biology · 2026Article
- Stabilizing Plasmodium falciparum proteins for small molecule drug discovery.Protein science : a publication of the Protein Society · 2026Article
- Limitations of the refolding pipeline for de novo protein design.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
With the emergence of powerful deep learning-based tools, computational protein design has become a widely accessible technique. Nowadays, it is possible to perform both sequence and structure design in a matter of minutes, making the technology attractive to the broader scientific community. In protein design campaigns, one of the most common in silico strategies to evaluate how well a sequence encodes a target structure is the so-called self-consistency or refolding pipeline. In this approach, a structure prediction model is used to refold the designed sequence to probe whether it is compatible with the intended structure, and is evaluated via two metrics linked to experimental success: the confidence score of the predicted structure (predicted local distance difference test) and the self-consistency root-mean-square deviation, which measures how closely the refolded structure matches the target. In this work, we systematically evaluate how different models and structure prediction settings impact these metrics, and to what extent they can be used to reliably filter sequence design candidates. We show that evolutionary information can obscure folding models' abilities to assess sequence-structure compatibility, reducing the predictive performance of refolding metrics for experimental success, particularly for designs that share homology with natural sequences. We further highlight limitations of refolding metrics, including their sensitivity to structural features, such as flexibility. Our findings raise awareness of potential pitfalls in refolding-based evaluation and support more informed use of these metrics in protein design campaigns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.